The Oncosearch | Oncotarget

Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms Case Report

Patrizia Gentilini, Janci C. Lindsay, Nafuko Konishi, Masanori Fukushima, Panagis Polykretis

Published Mar 30, 2026 · Vol. 17, No. 1 · pp. 34-49

Keywords: COVID-19 genetic vaccines, adverse effects, cancer, lymphoblastic leukaemia, lymphoblastic lymphoma

Machine learning-based survival prediction in colorectal cancer combining clinical and biological features Research Paper

Lucas M. Vieira, Natasha A.N. Jorge, João B. Sousa, João C. Setubal, Peter F. Stadler, Maria E.M.T. Walter

Published Dec 2, 2025 · Vol. 16, No. 1 · pp. 834-847

Keywords: colorectal cancer, machine learning, feature selection, non-coding RNAs, genes

Mechanism of anticancer action of bifidobacterium: Insights from gut microbiota Review

Hoang Do, Esther Asiamah, Mayanijesu Olorife, Arathi Pillai, Sakshi Patel, Ponniah Selvakumar, Sidhartha D. Ray, Ashakumary Lakshmikuttyamma

Published Nov 6, 2025 · Vol. 16, No. 1 · pp. 818-833

Keywords: cancer, gut microbiota, bifidobacterium

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma Research Paper

Leonardo Gomes da Fonseca, Federico Piñero, Margarita Anders, Carla Bermudez, Ezequiel Demirdjian, Adriana Varón, Daniela Perez, Jorge Rodriguez, Oscar Beltrán, Ezequiel Ridruejo, Pablo Caballini, Alexandre Araujo, Juan Diego Torres Florez, Juan Ignacio Marín, Marina Villa, Federico Orozco, Jaime Poniachik, Sebastián Marciano, Fernando Bessone, Manuel Mendizabal

Published May 8, 2025 · Vol. 16, No. 1 · pp. 348-360

Keywords: liver cancer, immunotherapy, adverse events, immunology, real-world

Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer Research Paper

Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, Khoi Chu, Akshara Singareeka Raghavendra, Clinton Yam, Lumarie Santiago, Beatriz E. Adrada, Padmanee Sharma, Elizabeth A. Mittendorf, Jennifer K. Litton

Published Mar 2, 2024 · Vol. 15, No. 1 · pp. 238-247

Keywords: breast cancer, ER positive, immunotherapy, neoadjuvant chemotherapy, tumor microenvironment

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma Addendum

Eduard Teixidor, Elia Sais, Carmen Amalia Vásquez, Walter Carbajal, Alejandro Hernández, Gloria Sánchez, Angel Izquierdo, Sara Verdura, Javier A. Menéndez, Joaquim Bosch-Barrera

Published Jun 27, 2023 · Vol. 14, No. 1 · pp. 668-668

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) Research Paper

Leo I. Gordon, Reem Karmali, Jason B. Kaplan, Rakesh Popat, Howard A. Burris III, Silvia Ferrari, Sumit Madan, Manish R. Patel, Giuseppe Gritti, Dima El-Sharkawi, F. Ian Chau, John Radford, Jaime Pérez de Oteyza, Pier Luigi Zinzani, Swaminathan P. Iyer, William Townsend, Harry Miao, Igor Proscurshim, Shining Wang, Shilpi Katyayan, Ying Yuan, Jiaxi Zhu, Kate Stumpo, Yaping Shou, Cecilia Carpio, Francesc Bosch

Published Jan 20, 2023 · Vol. 14, No. 1 · pp. 57-70

Keywords: Non-Hodgkin’s lymphoma, DLBCL, relapsed/refractory, SYK inhibitor, TAK-659

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program Research Paper

Reyes Bernabé-Caro, Pilar Garrido, Rosario García-Campelo, Ramón Palmero, Ángel Artal, Cristina Bayona, Delvys Rodríguez-Abreu, Marta López-Brea, Alfredo Paredes, David Vicente, José Miguel Sánchez Torres, Margarita Majem, Pilar Diz, Rocío Gordo, Margarita Coca, Javier de Castro

Published Jun 7, 2022 · Vol. 13, No. 1 · pp. 812-827

Keywords: ALK-positive NSCLC, ALK inhibitor, crizotinib, alectinib, unselected patient

Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma Case Report

Eugene J. Vaios, Kristen A. Batich, Anne F. Buckley, Anastasie Dunn-Pirio, Mallika P. Patel, John P. Kirkpatrick, Ranjit Goudar, Katherine B. Peters

Published Mar 15, 2022 · Vol. 13, No. 1 · pp. 576-582

Keywords: radiation necrosis, brain tumor, primary CNS lymphoma, stereotactic radiosurgery, bevacizumab

The long winding road to the safer glucocorticoid receptor (GR) targeting therapies Review

Ekaterina A. Lesovaya, Daria Chudakova, Gleb Baida, Ekaterina M. Zhidkova, Kirill I. Kirsanov, Marianna G. Yakubovskaya, Irina V. Budunova

Published Feb 1, 2022 · Vol. 13, No. 1 · pp. 408-424

Keywords: glucocorticoid receptor, glucocorticoids, SEGRAM, REDD1, drug repurposing

Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma Review

John T. Lear, Reinhard Dummer, Alexander Guminski

Published Dec 1, 2021 · Vol. 12, No. 26 · pp. 2531-2540

Keywords: adverse events, basal cell carcinoma, sonidegib, hedgehog inhibitor, drug scheduling

TP53 mutations determined by targeted NGS in breast cancer: a case-control study Research Paper

Angeliki Andrikopoulou, Evangelos Terpos, Spyridoula Chatzinikolaou, Kleoniki Apostolidou, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Flora Zagouri

Published Sep 2, 2021 · Vol. 12, No. 21 · pp. 2206-2214

Keywords: TP53 mutations, next-generation sequencing, biomarker, prognosis, breast cancer

Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma Research Paper

Ricardo Paz-Fumagalli, Jacob Core, Carlos Padula, Seyed Montazeri, John McKinney, Gregory Frey, Zlatko Devcic, Andrew Lewis, Charles Ritchie, Kabir Mody, Sunil Krishnan, Beau Toskich

Published Aug 21, 2021 · Vol. 12, No. 20 · pp. 2075-2088

Keywords: Yttrium-90, radioembolization, cholangiocarcinoma, angiography, radiation dosimetry

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma Research Perspective

Anjan Thakurta, William E. Pierceall, Michael D. Amatangelo, Erin Flynt, Amit Agarwal

Published May 19, 2021 · Vol. 12, No. 15 · pp. 1555-1563

Keywords: multiple myeloma, combinations, immunomodulatory agents, apoptosis, protein degradation

Multigene tests for breast cancer: the physician’s perspective Review

Francesco Cognetti, Laura Biganzoli, Sabino De Placido, Lucia del Mastro, Riccardo Masetti, Giuseppe Naso, Giancarlo Pruneri, Donatella Santini, Carlo Alberto Tondini, Corrado Tinterri, Giuseppe Tonini, Sandro Barni

Published Apr 8, 2021 · Vol. 12, No. 9 · pp. 936-947

Keywords: genomic tests, breast cancer, adjuvant chemotherapy, adjuvant hormone therapy

Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity Research Paper

Leonardo G. da Fonseca, Carla Fuster-Anglada, Cristina Carrera, Cristina Millán, Esther Samper, Victor Sapena, Álvaro Díaz-González, Marco Sanduzzi-Zamparelli, Cassia Leal, Alejandro Forner, Jordi Bruix, Maria Reig, Loreto Boix, Alba Díaz

Published Feb 5, 2021 · Vol. 12, No. 5 · pp. 440-449

Keywords: hepatocellular carcinoma, tyrosine kinase inhibitors, treatment adverse events, skin lesions, molecular profiling

PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer Research Paper

Michael Rees, Chris Smith, Peter Barrett-Lee, Steve Hiscox

Published Dec 11, 2020 · Vol. 11, No. 51 · pp. 4722-4734

Keywords: breast cancer, PELP-1, ER+, invasion

Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak Research Perspective

Flávia Dias Xavier, Fernando Sergio Blumm Ferreira, Rodrigo Martins Abreu

Published Nov 10, 2020 · Vol. 11, No. 47 · pp. 4371-4386

Keywords: healthcare, multiple myeloma, adherence, elderly, refractory/relapsed

Phase I dose escalation study of 12b80 (hydroxybisphosphonate linked doxorubicin) in naturally occurring osteosarcoma Research Paper

Pierre Boyé, Emmanuelle David, François Serres, Quentin Pascal, Franck Floch, Kévyn Geeraert, Virginie Coste, Laurent Marescaux, Sébastien Cagnol, Jean-Yves Goujon, Maxim Egorov, Ronan Le Bot, Dominique Tierny

Published Nov 3, 2020 · Vol. 11, No. 46 · pp. 4281-4292

Keywords: bisphosphonate, bone targeting, canine, doxorubicin, osteosarcoma

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma Research Perspective

Christie P.M. Verkleij, Kristine A. Frerichs, Marloes Broekmans, Saida Absalah, Patricia W.C. Maas-Bosman, Sandy Kruyswijk, Inger S. Nijhof, Tuna Mutis, Sonja Zweegman, Niels W.C.J. van de Donk

Published Oct 24, 2020 · Vol. 11, No. 45 · pp. 4076-4081

Keywords: multiple myeloma, bispecific antibody, immunotherapy, BCMA, CD38

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms Case Report

Machine learning-based survival prediction in colorectal cancer combining clinical and biological features Research Paper

Mechanism of anticancer action of bifidobacterium: Insights from gut microbiota Review

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma Research Paper

Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer Research Paper

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma Addendum

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) Research Paper

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program Research Paper

Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma Case Report

The long winding road to the safer glucocorticoid receptor (GR) targeting therapies Review

Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma Review

TP53 mutations determined by targeted NGS in breast cancer: a case-control study Research Paper

Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma Research Paper

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma Research Perspective

Multigene tests for breast cancer: the physician’s perspective Review

Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity Research Paper

PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer Research Paper

Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak Research Perspective

Phase I dose escalation study of 12b80 (hydroxybisphosphonate linked doxorubicin) in naturally occurring osteosarcoma Research Paper

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma Research Perspective

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Exploring the potential link between mRNA COVID-19 vaccinations and cancer: A case report with a review of haematopoietic malignancies with insights into pathogenic mechanisms Case Report

Machine learning-based survival prediction in colorectal cancer combining clinical and biological features Research Paper

Mechanism of anticancer action of bifidobacterium: Insights from gut microbiota Review

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma Research Paper

Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer Research Paper

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma Addendum

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659) Research Paper

Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program Research Paper

Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma Case Report

The long winding road to the safer glucocorticoid receptor (GR) targeting therapies Review

Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma Review

TP53 mutations determined by targeted NGS in breast cancer: a case-control study Research Paper

Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma Research Paper

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma Research Perspective

Multigene tests for breast cancer: the physician’s perspective Review

Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity Research Paper

PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer Research Paper

Treatment of elderly patients with refractory/relapsed multiple myeloma: oral drugs adherence and the COVID-19 outbreak Research Perspective

Phase I dose escalation study of 12b80 (hydroxybisphosphonate linked doxorubicin) in naturally occurring osteosarcoma Research Paper

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma Research Perspective